Premium
Bronchodilating activity of oral clenbuterol in asthmatic children after single administration of different dosages
Author(s) -
Boner A. L.,
Bennati D.,
Castellani C.,
Sette L.,
Schiassi M.
Publication year - 1987
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950030110
Subject(s) - clenbuterol , medicine , dose , placebo , asthma , ingestion , oral administration , bronchodilator , anesthesia , heart rate , dose–response relationship , crossover study , bronchoconstriction , blood pressure , alternative medicine , pathology
The dose‐response activity of clenbuterol, a new long‐acting β 2 ‐agonist, was evaluated in 12 children aged 5 to 11 years with moderate to severe asthma. The study was a double‐blind cross‐over comparison of three oral dose levels: 0.5, 1.0, and 1.5 μg/kg and placebo all in the form of syrup. Pulmonary function, heart rate, blood pressure, and tremor were evaluated at 30, 60, 90, and 120 min, then hourly for 8 hr, following the ingestion of the drug. The bronchodilating effect of clenbuterol, evaluated as percentage changes in expiratory flow rates was significantly different from placebo. The overall fall‐off in the effect of 1.0 μg/kg and 1.5 μg/kg doses after 8 hr was small. The results of the 1.0 μg/kg dose often overlapped those of the 1.5 μg/kg dose, suggesting that a single 1.0 μg/kg dose of clenbuterol is most advisable in children, assuring the most favorable risk/benefit ratio. Even the highest dose of clenbuterol caused only a marginal increase in tremor, not statistically different from that induced by placebo. Pediatr Pulmonol 1987; 3; 34–37 .